Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

Cancer

Volumn 95, Issue 10, 2002, Pages 2223-2229

  Fracasso, Paula M ^a,b   Blum, Kristie A ^a,b   Tan, Benjamin R ^a,b   Fears, Carole L ^a,b   Bartlett, Nancy L ^a,b   Arquette, Matthew A ^a,b   Clark, Romnee S ^a,b,c  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Doxil ; Gemcitabine; Gemzar ; Palmar plantar erythrodysesthesia; Pegylated liposomal doxorubicin; Phase I

Indexed keywords

DOXORUBICIN; GEMCITABINE; MITOXANTRONE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HUMAN; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN DISEASE; SOLID TUMOR; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

EID: 0037110626     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10937     Document Type: Article

References (18)

1. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995;13:1777-1785.
2. Rivera E, Valero V, Syrewicz L, et al. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001;19:1716-1722.
3. Tobias DH, Runowicz C, Mandeli J, et al. A phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer [Abstract]. Proc Am Soc Clin Oncol. 2000;19:392a.
4. Burstein HJ, Ramirez MJ, Petros WP, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999;10:1113-1116.
5. Woll PJ, Carmichael J, Calvert AH, et al. Doxil/Caelyx plus paclitaxel in patients with metastatic breast cancer: Update of a phase II efficacy and safety study [Abstract]. Proc Am Soc Clin Oncol. 2001;20:67b.
6. Saprano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol. 2001;19:3117-3125.
7. Ryan CW, Fleming GF, Janisch L, et al. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000;23:297-300.
8. Abbruzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
9. Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15: 310-316.
10. Perez-Manga G, Lluch A, Alba E, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial. J Clin Oncol. 2000;18:2545-2552.
11. Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2000;18:840-846.
12. Singal PK, Iliskovic N. Current concepts: Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905.
13. Hengge UR, Esser S, Rudel HP, et al. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer. 2001;37:878-883.
14. 2. Ann Oncol. 2000;11:1029-1033.
15. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol. 1995; 13:2731-2736.
16. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol. 2000;18:2615-2619.
17. Patel S, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483-3489.
18. vonMinckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853-855.